Why it matters: Metabolic syndrome and type 2 diabetes risk increase with age
slow 8-week regimens brought it to 0-3.8%, near placebo, at no efficacy cost (Frias 2020): Frias Lancet 2018
If you are exploring peptide therapy and want guidance you can trust, we invite you to call us at (843) 375-6588 or complete our contact form to learn how we can help you move forward safely
Stable gastric pentadecapeptide BPC 157 [129,130,131,132,133,134,135,136,137,138,139,140,141,142,168] has proven its effectiveness in resolving these harmful events, counteracting brain, heart, lung, liver, kidney, and gastrointestinal tract lesions, arrhythmias, hemorrhage (brain, lung), and thrombosis, peripherally and centrally, intracranial hypertension, portal hypertension, caval hypertension, and aortic hypotension, which are markedly attenuated or even eliminated, with advanced Virchow triad circumstances fully reversed
For GHK-Cu specifically, the logic is sound even without direct evidence: cumulative copper exposure is lower with reduced frequency, and the gene expression changes initiated during loading persist during maintenance
